DNA-bound proteins released from traps cast by neutrophils, a type of immune cell, may help predict which lupus…
Articles by Margarida Maia
People with lupus nephritis who are in clinical remission, with no symptoms for at least one year, are 82% less…
When the protein TLR7, or toll-like receptor 7 — which normally triggers an immune response against viruses and bacteria —…
China’s regulatory body has given Gracell Biotechnologies the green light to launch a Phase 1/2 clinical trial testing GC012F,…
Otsuka Pharmaceutical is seeking approval in Japan to manufacture and market Lupkynis (voclosporin) for the treatment of lupus nephritis,…
A CAR T-cell therapy targeting B-cells, a type of immune cells, was found to clear disease-causing autoantibodies from the bloodstream…
Kyverna Therapeutics has signed a research funding deal with Charité – Universitätsmedizin Berlin, in Germany, to study how therapies…
Lupkynis (voclosporin) continues to be safe and to protect kidney function when taken for up to three years by…
The Lupus Research Alliance has named the winners of this year’s Awards to Promote Diversity in Lupus Research, all…
Trethera will use a $0.6 million Small Business Technology Transfer (STTR) grant to advance TRE-515, its lead candidate for…